Effect of two vitamin D repletion protocols on 24-h urine calcium in patients with recurrent calcium kidney stones and vitamin D deficiency: a randomized clinical trial.
24-h urine
Hypercalciuria
Urolithiasis
Vitamin D deficiency
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
22 Jul 2023
22 Jul 2023
Historique:
received:
15
10
2022
accepted:
13
07
2023
medline:
23
10
2023
pubmed:
23
7
2023
entrez:
22
7
2023
Statut:
epublish
Résumé
To evaluate the effects of two vitamin D repletion therapies (cholecalciferol) on serum levels of 25-hydroxyvitamin D (25(OH)D) and 24-h urine calcium in patients with recurrent calcium kidney stones and vitamin D deficiency (VDD). A parallel-group randomized controlled clinical trial on patients who referred to Labbafinejad kidney stone prevention clinic, Tehran, Iran. From 88 recurrent calcium stone formers, 62 patients completed the study. The age of participants was 18-70 years who had serum 25(OH)D levels of 10-20 ng/ml. Participants received oral cholecalciferol 2000 IU daily for 12 weeks or 50,000 IU weekly for 8 weeks. Study variables including 24-h urine calcium, supersaturations of calcium oxalate and calcium phosphate, serum 25(OH)D and parathyroid hormone were measured at the beginning of the study and after 12 weeks. The 24-h urine calcium significantly increased in both groups (β = 69.70, p < 0.001), with no significant difference between treatments. Both groups showed no significant change in the supersaturation levels of calcium oxalate and calcium phosphate. Serum levels of 25(OH)D increased significantly (β = 12.53, p < 0.001), with more increase in the 50,000 IU group (β = 3.46, p = 0.003). Serum parathyroid hormone decreased in both groups (p < 0.001). Although both treatment protocols increased 24-h urine calcium, they did not increase the supersaturation state of calcium oxalate or calcium phosphate. Trial registration IRCT20160206026406N4, 13/08/2019.
Identifiants
pubmed: 37481570
doi: 10.1186/s40001-023-01226-z
pii: 10.1186/s40001-023-01226-z
pmc: PMC10362614
doi:
Substances chimiques
Calcium
SY7Q814VUP
Calcium Oxalate
2612HC57YE
calcium phosphate
97Z1WI3NDX
Calcium Phosphates
0
Cholecalciferol
1C6V77QF41
Parathyroid Hormone
0
Vitamin D
1406-16-2
Vitamins
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
246Informations de copyright
© 2023. The Author(s).
Références
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30
pubmed: 21646368
Clin J Am Soc Nephrol. 2013 Nov;8(11):1960-7
pubmed: 23929928
Can Urol Assoc J. 2015 Nov-Dec;9(11-12):403-8
pubmed: 26788229
N Engl J Med. 2007 Jul 19;357(3):266-81
pubmed: 17634462
Urology. 2016 Jan;87:40-5
pubmed: 26494294
J Ren Nutr. 1998 Jul;8(3):127-31
pubmed: 9724501
N Engl J Med. 2002 Jan 10;346(2):77-84
pubmed: 11784873
Can Urol Assoc J. 2016 Nov-Dec;10(11-12):E347-E358
pubmed: 28096919
Int Braz J Urol. 2019 Mar-Apr;45(2):340-346
pubmed: 30735332
Curr Opin Nephrol Hypertens. 2013 Jul;22(4):383-9
pubmed: 23739765
BJU Int. 2019 May;123(5):751-752
pubmed: 30576591
J Nutr Sci. 2021 Dec 13;10:e106
pubmed: 35059187
J Urol. 2017 Apr;197(4):1079-1083
pubmed: 27765695
Curr Opin Nephrol Hypertens. 2019 Mar;28(2):148-153
pubmed: 30531469
Rev Endocr Metab Disord. 2017 Jun;18(2):153-165
pubmed: 28516265
J Urol. 2018 May;199(5):1262-1266
pubmed: 29132983
Int Urol Nephrol. 2016 Aug;48(8):1243-1246
pubmed: 27093967
Iran J Kidney Dis. 2019 Jan;13(1):27-31
pubmed: 30851716
Nutrients. 2015 Jun 25;7(7):5111-42
pubmed: 26121531
World J Urol. 2021 Feb;39(2):597-603
pubmed: 32367158
Kidney Int. 2000 Mar;57(3):1115-23
pubmed: 10720964
J Clin Endocrinol Metab. 2012 Nov;97(11):3989-95
pubmed: 22933544
Clin J Am Soc Nephrol. 2012 May;7(5):829-34
pubmed: 22422535
Iran J Kidney Dis. 2021 Jul;15(4):263-269
pubmed: 34278997